chartexchange

IBRX261127C00010500
IBRX Nov 27 2026 10.50 Call
optionOPRA

EODOct 16, 2026
0.85USD-39.286%(-0.55)6Vol103OI
Loading…
Underlying
Underlying Price
$8.48
Type
Call
Strike
10.5
Expiration
Nov 27, 2026
DTE
38d
Moneyness
OTM
Intrinsic
$0.00
IBRX 10.5 Call Across Expirations
ExpirationDTELastChangeVolOpen Int
Oct 23, 20263d$0.15-57.14%2271,477
Oct 30, 202610d$0.22-60.00%64468
Nov 6, 202617d$0.65-14.47%444
Nov 13, 202624d$0.61-33.70%1356
Nov 27, 202638d$0.85-39.29%6103
IBRX Nearby Strikes · Nov 27, 2026
StrikeLastChangeVolOpen IntMoneyness
7.5 C$3.08+0.00%3030ITM
8 C$1.90-25.49%211ITM
8.5 C——00OTM
9 C$1.86+0.00%1010OTM
9.5 C$1.20-41.46%1220OTM
10 C$1.00-31.03%386OTM
10.5 C$0.85-39.29%6103OTM
11 C$1.02+27.50%66OTM
11.5 C——00OTM
12 C$0.85-6.59%23OTM
12.5 C——00OTM
13 C——00OTM
13.5 C——00OTM
IBRX Profile

immunitybio is a leading registration-stage immuno-oncology and infectious disease company activating both the innate (natural killer cell and macrophage) and adaptive (t cell) immune system. we are developing molecular and product platforms including n-803, aldoxorubicin, and a second-generation adenovirus vector, which are based upon our three key modalities of activating natural killer ('nk') and t cells, tumoricidal macrophages, and memory t cells.